Researchers discover new battleground for viruses and immune cells

Vaccines have led to many of the world’s greatest public health triumphs, but many deadly viruses, such as HIV, still elude the best efforts of scientists to develop effective vaccines against them. An improved understanding of how the immune system operates during a viral infection is critical to designing successful anti-virus vaccines. Scientists from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), have added an important dimension to this knowledge.

Focusing on mouse lymph nodes—bean-shaped organs that contain a variety of immune cells and are distributed throughout the body—the researchers discovered that immune cells confront viruses just inside of the lymph node and not deep within these organs as previously thought. The study, led by Jonathan Yewdell, M.D., Ph.D., chief of the NIAID Cellular Biology Section and his NIAID colleague, Heather Hickman, Ph.D., is described in a report online in Nature Immunology.

The results are significant, the authors say, as they observed in detail the interaction of viruses and immune cells inside a living organism, in this case, mice. Combining expertise from disciplines such as imaging, immunology, virology and other specialties, the scientists first extracted and then purified specific T cells—killer T cells—from mice.

Killer T cells, which attack and kill infected or cancerous cells, are major weapons in the immune system arsenal. The scientists labeled the T cells with a fluorescent marker, injected them back into the mice, and then infected the animals with vaccinia virus, the virus used to make smallpox vaccine, engineered to express a brilliantly colored protein.

Using a multiphoton microscope, a highly specialized microscope that enables scientists to peer into a living organism, the scientists could now look into the lymph nodes of the infected mice and see that the viruses had infected cells just inside the lymph node surface, triggering a swarm of T cells. These virus-specific T cells form an elaborate and dynamic communications network that activates them to divide and travel to the site of viral infection, where they kill virus-infected cells.

“A key challenge in viral vaccine research is developing strategies for immunizing against lethal viruses such as HIV that have eluded the standard vaccine approaches,” notes Dr. Yewdell. “We have contributed a page to the handbook of understanding how to rationally design vaccines to elicit a T-cell response.” According to the NIAID team, pinpointing where in the lymph node immune cells fight the virus should help efforts to design effective anti-virus vaccines.

Source: National Institute of Allergy and Infectious Diseases

Related stories:

Sensitive nanowire disease detectors made by Yale scientists
Yale scientists have created nanowire sensors coupled with simple microprocessor electronics that are both sensitive and specific enough to be used for point-of-care (POC) disease detection, according to a report in Nano Letters.
Scientists Find First Immune Responses to HIV Infection Ineffective
(PhysOrg.com) -- Scientists have identified the very first antibodies to appear in the wake of HIV infection and have concluded that they are virtually impotent in mounting a meaningful defense against the invading virus.
HIV drug maraviroc effective for drug-resistant patients
As many as one quarter of HIV patients have drug resistance, limiting their treatment options and raising their risk for AIDS and death. Now, maraviroc, the first of a new class of HIV drugs called CCR5 receptor antagonists, has been shown to be effective over 48 weeks for drug-resistant patients with R5 HIV-1, a variation of the virus found in more than half of HIV-infected patients.
Existing anti-obesity drugs may be effective against flu, hepatitis and HIV
Viruses dramatically increase cellular metabolism, and existing anti-obesity drugs may represent a new way to block these metabolic changes and inhibit viral infection, according to a study published today in the journal Nature Biotechnology.
A new therapeutic option for human hepatocyte cancer
p53-impaired tumors may be particularly suitable to parvovirus H-1-induced therapy. Although the p53 deficiency in tumors may induce resistance to chemotherapeutic agents, this will not affect the tumor cell susceptibility to H-1 PV-induced oncolytic infections. The parvovirus H-1 may also overcome other tumor resistance mechanisms developed in these tumor entities. So H-1 PV is a suitable agent to circumvent the resistance of p53-negative human hepatocellular carcinoma (HCC) cells to genotoxic agents, and enhances the apoptotic process which is dependent on functional PML. Thus, H-1 PV may be considered as therapeutic options for HCC, especially for p53-negative tumors.
'Friendly' bacteria protect against type 1 diabetes
In a dramatic illustration of the potential for microbes to prevent disease, researchers at Yale University and the University of Chicago showed that mice exposed to common stomach bacteria were protected against the development of Type I diabetes.
Viral 'magic bullet' targets cancer cells with help of new compound
Researchers at McGill University and the affiliated Lady Davis Research Institute of the Jewish General Hospital – along with colleagues at the University of Ottawa and the Ottawa Health Research Institute (OHRI)–report a significant breakthrough in the use of viruses to target and destroy cancer cells, a field known as oncolytic virotherapy. Their results were published in the September early edition of the Proceedings of the National Academy of Sciences (PNAS).
Pores open the door to death
(PhysOrg.com) -- Our body is almost constantly being threatened by pathogens and cancerous cells that appear out of the blue. But the body puts up a fight: specialized cells in the immune system smuggle small molecules (granzymes) into cancer cells and those body cells that have fallen prey to viruses. The molecules then trigger off the diseased cells' built-in suicide program. There are two possible ways in which the granzymes gain entry into the cells under attack.

News discussion:

Medicine & Health news